Navigation Links
Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform

REDWOOD CITY, Calif., Oct. 28, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. presented data elucidating the robust aerosol performance and physicochemical foundations of the Company's cosuspension technology which uses spray-dried, low-density porous particles to deliver drug microcrystals via pressurized metered dose inhalers (MDIs). Two posters were presented this week at the 25th American Association of Pharmaceutical Scientists annual meeting in Washington DC.

"These results demonstrate the flexibility of Pearl's metered dose inhaler platform for multiple drugs and combinations," said Sarvajna Dwivedi, Ph.D., Pearl's cofounder and executive vice president, research and development. "The research conducted at Pearl has improved our understanding of the structure of porous particles and their constituents well beyond that of four years ago when Pearl first licensed its porous particle technology. As a result of such scientific progress, the Company has filed several new patent applications globally, which we believe will offer broad protection for our pipeline of respiratory products."

In vitro drug delivery performance data of Pearl's lead candidate for COPD, PT003, a cosuspension of formoterol fumarate (FF) and glycopyrrolate (GP), as well as a triple combination cosuspension of FF, GP and mometasone furoate (MF), an inhaled corticosteroid, were presented at the AAPS meeting, along with the results of each individual drug's cosuspension. Results demonstrate that Pearl's proprietary cosuspension technology enables consistent aerosol performance that is equivalent for all cosuspended drugs regardless of dose for mono, dual and triple combinations, without changing the nature of porous particles for each product type. Further analyses presented by Pearl scientists at AAPS show solid state structural details and thermal properties of the porous particles, which provide the Company's cosuspensions with their characteristically long room-temperature shelf life.

Pearl's president and chief executive officer, Chuck Bramlage added, "Pearl has long held a commitment not only to pipeline progression but to fundamental scientific excellence, two elements that we feel are essential when establishing a high value company. We believe these strengths will propel the current Pearl pipeline and sustain our future growth through innovation."

Poster Details
Date & Time: Wednesday, October 26, 2011; 1:00pm – 4:30pm
Location: Hall C
Title: "Thermodynamic and Structural effects of CaCl2 on the Phase Transitions and Structures of Distearoyl-Phosphatidylcholine (DSPC) by Differential Scanning Calorimetry and X-Ray Diffraction"

Date & Time: Thursday, October 27, 2011; 8:00am - 12:00pm
Location: Hall C
Title: "A New Formulation Platform for Metered Dose Inhaler Combination Products:  Cosuspensions of Engineered Phospholipid Microparticles with Micronized Actives"

Reproduction of these posters may be retrieved from the Publications page of the Pearl website.

About COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment. Pearl is developing inhaled combination products designed to optimize the treatment of COPD.

About Pearl Therapeutics

Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT001 are developed with Pearl's proprietary porous particle cosuspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
2. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
3. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
4. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
5. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
6. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
7. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
8. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
9. Anthera Announces Last Patient Enrolled in PEARL-SC Study
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Enova Illumination is pleased to ... Helsinki, Finland to combine their world ... the cutting edge of medical visualization: Enova is the ... the United States and Novocam is the ... provide the world,s most powerful battery-operated LED headlight with ...
(Date:11/24/2015)... Nov. 24, 2015 Abaxis, Inc. (NasdaqGS: ... and consumables for the medical, research, and veterinary markets ... Financial Officer, will present at the 27 th ... 2015 at 11:30 a.m. ET. The conference will be ... New York City . Abaxis, ...
(Date:11/24/2015)...   Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... sealant technology (MAST) platform to develop novel therapies for ... that the Company,s Chief Executive Officer, Brian M. ... th Annual Healthcare Conference on Tuesday, December 1, ... Palace hotel in New York City ...
Breaking Medicine Technology:
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... ... sizes, has launched their Black Friday sale a week early, offering 40% off ... to transform the intimate apparel industry through both mobile fit technology and the ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Preparing for the ... – 3:00 p.m. EST, , FDA has long asserted that design ... apply to performing the tests and do not meet the device regulations. , Come ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), ... & Company as its newest Partner Firm. Based in Jefferson City, Missouri, their ... trusted advisor regardless of whether that client is a business, a family, or ...
(Date:11/24/2015)... ... 2015 , ... With Thanksgiving right around the corner, holiday travel season is ... your family and vehicle. , According to the National Highway Traffic Safety Administration, 301 ... sharing the following safety tips from the NHTSA: , ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered a ... Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea through ... a Koala Center for Sleep Disorders in the US, one of four in the Illinois ...
Breaking Medicine News(10 mins):